View AllPharmaBiotechMedical
4 October 2018
Request to re-open Glaxo ‘dual pricing’ case rejected by General Court: The end of the road for challenges to dual pricing?

Entering into agreements that erect barriers to parallel exports between EU markets is generally a...

14 August 2018
Concordia and the CMA – a drama in (at least) three parts

Last week, Concordia International released a management report in which it announced the names of six drugs...

30 July 2018
The EMA’s clinical data publication policy: 1 year on

On 16 July 2018, the EMA published a report on the first year (Oct 2016...

4 July 2018
CJEU follows Advocate General’s Opinion to confirm the scope of the Specific Mechanism

On 21 June 2018 the CJEU gave its judgment in a preliminary reference from the...

20 June 2018
The CAT sets a clear framework for excessive and unfair prices in its Pfizer/Flynn judgment

The Competition Appeal Tribunal (CAT) recently gave its judgment in Pfizer and Flynn’s appeal of...

14 May 2018
Depression Delayed: CMA’s paroxetine pay-for-delay case heads to Luxembourg

On 8 March 2018, the Competition Appeal Tribunal (CAT) gave an initial judgment in appeals brought by...

5 April 2018
We have our transition period for goods but what about the regulations? How the life sciences industry may be affected by Brexit

The European Commission published a Draft Withdrawal Agreement (the Agreement) on 19 March 2018. The Agreement...

16 February 2018
Different types of value transfer in ‘reverse payment’ settlement agreements

In recent years, competition authorities and courts in the EU and the US have paid...

9 February 2018
Specific Mechanism applies to extended SPC period opines AG Tanchev

On 7 February 2018 Advocate General Tanchev delivered his opinion in Pfizer Ireland Pharmaceuticals v...

29 January 2018
10 key points on Parallel Trade and Pharma

Parallel trade is the cross-border sale of goods within the EU by traders outside of...

24 January 2018
Evolving how English courts construe written commercial contracts (Teva v AstraZeneca)

Teva v AstraZeneca [2017] EWCA Civ 2135 is the latest case in a line of cases...

24 January 2018
Misleading information and competition law - Case C-179/16 CJEU Judgment of 23 January 2018 (Avastin/Lucentis –Italy)

This case relates to the interplay between EU competition law and the pharmaceutical regulatory regime....